Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158643 | 0.83 | TAS1R3 (0.55) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL5592854 | 0.83 | TP53 (0.69) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL31235656 | 0.83 | HDAC1 (0.76) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL9212451 | 0.83 | HDAC1 (0.76) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL8292253 | 0.83 | TP53 (0.68) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL19476629 | 0.83 | TP53 (1.00) | TP53SMN1; SMN2ALDH1A1HPGDNPC1 | |
| SCHEMBL11379610 | 0.83 | SMN1; SMN2 (0.73) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL9690588 | 0.82 | SMN1; SMN2 (0.63) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL10842922 | 0.82 | TP53 (0.63) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 | |
| SCHEMBL5095558 | 0.82 | SMN1; SMN2 (0.63) | TP53SMN1; SMN2ALDH1A1HPGDTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2015021943-A9 | INDUCING NEUROGENESIS BY AXIN ENHANCER | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-12-30 | — | — | WO | disclosed |
| US-20150064112-A1 | USE OF T1R3 VENUS FLYTRAP REGION POLYPEPTIDE TO SCREEN FOR TASTE MODUALTORS | SENOMYX, INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2015021943-A1 | INDUCING NEUROGENESIS BY AXIN ENHANCER | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-02-19 | — | — | WO | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | TP53 2609/4885SMN1; SMN2 3773/4885ALDH1A1 3556/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | TP53 2609/4885SMN1; SMN2 3773/4885ALDH1A1 3556/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | TP53 2609/4885SMN1; SMN2 3773/4885ALDH1A1 3556/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | TP53 1423/4885SMN1; SMN2 2323/4885ALDH1A1 854/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | TP53 524/4885SMN1; SMN2 3613/4885ALDH1A1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.